Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After golf on WRAL: 3 people saved from the Neuse River. How they were rescued and urgent safety warnings authorities are issuing
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
CG Oncology, Inc. - Common stock
(NQ:
CGON
)
34.22
-0.18 (-0.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
468,517
Open
34.43
Bid (Size)
32.00 (2)
Ask (Size)
36.00 (1)
Prev. Close
34.40
Today's Range
33.77 - 35.24
52wk Range
25.77 - 50.23
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
August 08, 2024
CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Performance
YTD
-13.69%
-13.69%
1 Month
-6.81%
-6.81%
3 Month
+15.10%
+15.10%
6 Month
-22.88%
-22.88%
1 Year
-13.69%
-13.69%
More News
Read More
A Closer Look at 9 Analyst Recommendations For CG Oncology
June 28, 2024
Via
Benzinga
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Decoding 10 Analyst Evaluations For CG Oncology
May 14, 2024
Via
Benzinga
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
May 03, 2024
Via
Benzinga
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 03, 2024
Via
Benzinga
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
March 28, 2024
Via
Investor's Business Daily
Topics
Initial Public Offering
Exposures
Securities Market
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 28, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
February 27, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
February 25, 2024
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
3 attractive stocks that insiders are buying
February 12, 2024
Via
MarketBeat
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2024
From
CG Oncology, Inc.
Via
Business Wire
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
January 28, 2024
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 26, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.